


WM STUDY NOW ENROLLING!

Are You Living with Waldenström Macroglobulinemia (WM)?

WM clinical research study seeks volunteers

Clinical research studies help researchers learn about potential treatments. A clinical research study, or clinical trial, is now enrolling people living with Waldenström Macroglobulinemia (WM) who have a CXCR4 genetic variant, or mutation. Treatments that are available for WM, such as Imbruvica® (ibrutinib), are not as helpful for people with the CXCR4 variant.¹



About the study

-  This clinical research study will help researchers answer questions about the safety of the drug mavorixafor.
-  Mavorixafor pills are taken by mouth.
-  This is a Phase 1b study, which means researchers want to know what dosage of mavorixafor is safe.
-  Researchers will give study volunteers doses that go up over time, testing safety at each level. Volunteers may reach 200, 400 or 600 mg of mavorixafor.
-  Mavorixafor will be taken along with ibrutinib, an FDA-approved treatment for WM.
-  Researchers will observe volunteers for 28 days before the study starts, and then for 1 year during the study to determine safe dosing.
-  Researchers are studying mavorixafor as a treatment for WM at 6 centers around the world (4 of them in the U.S.) in partnership with The Leukemia and Lymphoma Society.

Who can join?

- Adults over the age of 18
- People with a WM diagnosis with MYD88 and CXCR4 genetic variants
- You may need to meet more criteria in order to join the study. To learn more, visit ClinicalTrials.gov and search for NCT04274738.

Why participate in a clinical study?

- More treatment options are needed for people living with WM. People who join this study may help researchers understand more about WM and find new treatments.
- Clinical studies are needed to make sure a medicine is safe and works before it is approved by the FDA.
- There is no cost to join the study. Expenses for medical care and travel are reimbursed by X4 Pharmaceuticals, the study sponsor.

LEARN MORE



Talk to your doctor to find out if this study is a good option for you.



Email
patientinfo@x4pharma.com

References

1. Castillo JJ, Xu L, Gustine JN, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. *Br J Haematol.* 2019;187(3):356-363. doi:10.1111/bjh.16088

Search ClinicalTrials.gov for NCT04274738